93 results
S-3ASR
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Automatic shelf registration
4:05pm
. Stichting Administratiekantoor Westend (the “Stichting”), as majority shareholder of Westend, controls Westend and accordingly, may be deemed
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
BM ≤3 indicates early dropouts
Paltusotine Showed Improvements in Flushing Frequency in Majority of Subjects End of each arrow represents the data
8-K
EX-10.1
CRNX
Crinetics Pharmaceuticals Inc
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
, and (ii) with respect to an amendment or waiver after the Closing, the Purchasers holding at least a majority of the outstanding Shares then held by all … , of shares of capital stock if, after such transfer, such person or group of affiliated persons would hold at least a majority of the outstanding voting
8-K
EX-10.2
4lxfvle 4l4p
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
8-K
EX-99.1
21rp4n2f
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-99.2
ay89utv9v5w
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
s2fvqnrbc9m1zcm qi
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-3.1
x7pzp4rve eclfa
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:35pm
424B5
iacwsyx6u1xritv iasf
13 Sep 23
Prospectus supplement for primary offering
5:19pm
424B5
ybbjk0h9pxze zu73d75
11 Sep 23
Prospectus supplement for primary offering
4:09pm